William Kormany

732 total citations
13 papers, 267 citations indexed

About

William Kormany is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, William Kormany has authored 13 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Public Health, Environmental and Occupational Health and 6 papers in Hematology. Recurrent topics in William Kormany's work include Acute Lymphoblastic Leukemia research (7 papers), CAR-T cell therapy research (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). William Kormany is often cited by papers focused on Acute Lymphoblastic Leukemia research (7 papers), CAR-T cell therapy research (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). William Kormany collaborates with scholars based in United States, France and Switzerland. William Kormany's co-authors include Juliann Paolicchi, Frank J. Ritter, Wendy G. Mitchell, Yu‐Tze Ng, Joan A. Conry, Stephen D. Collins, Katherine Tracy, Anthony S. Stein, Victoria M. Chia and Janet Franklin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

William Kormany

13 papers receiving 262 citations

Peers

Countries citing papers authored by William Kormany

Since Specialization

Citations

This map shows the geographic impact of William Kormany's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Kormany with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Kormany more than expected).

Fields of papers citing papers by William Kormany

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Kormany. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Kormany. The network helps show where William Kormany may publish in the future.

Co-authorship network of co-authors of William Kormany

This figure shows the co-authorship network connecting the top 25 collaborators of William Kormany. A scholar is included among the top collaborators of William Kormany based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Kormany. William Kormany is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial. 2024 ·Journal of Clinical Oncology ·Bob T. Li, Jeffrey Clarke, Enriqueta Felip, J.C. Ruffinelli, Pilar Garrido, Jon Zugazagoitia, Sarah B. Goldberg, Suresh S. Ramalingam, Iván Victoria, Sonam Puri, David R. Gandara, William Kormany, (unknown), Kerry Palmer, (unknown), Ramaswamy Govindan	8
2	Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors 2023 ·Molecular Cancer Therapeutics ·Jordi Rodón, Noboru Yamamoto, Toshihiko Doi, François Ghiringhelli, Maria-Elisabeth Goebeler, (unknown), Miguel A. Villalona‐Calero, Nicolas Penel, Amita Patnaik, Jean‐Pascal Machiels, Alfredo Addeo, James L. Abbruzzese, Sophie Postel‐Vinay, Sylvie Rottey, Chunxu Liu, Chen-Hua Chuang, William Kormany, Paul E. Hughes, Kiana Keyvanjah, Bert H. O’Neil	10
3	VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC 2023 ·Annals of Oncology ·Maximilian J. Hochmair, Karim Vermaelen, (unknown), Enric Carcereny, Christophe Dooms, SH Lee, (unknown), Terufumi Kato, T-E. Ciuleanu, Grace K. Dy, (unknown), Kenneth J. O’Byrne, (unknown), Gilberto de Castro, Nicolas Girard, Wendy Snyder, Qui Tran, William Kormany, Brett E. Houk, Alessandra Curioni‐Fontecedro	6
4	Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort 2022 ·Acta Haematologica ·Hiroaki Goto, Chitose Ogawa, Hiroatsu Iida, Keizo Horibe, Iekuni Oh, Satoru Takada, Yoshinobu Maeda, Hironobu Minami, Yasuhiro Nakashima, Joan Morris, William Kormany, Yuqi Chen, Toshihiro Miyamoto	1
5	Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. 2022 ·Journal of Clinical Oncology ·Miguel A. Villalona‐Calero, Amita Patnaik, Robert G. Maki, (unknown), James L. Abbruzzese, Ibiayi Dagogo‐Jack, Siddhartha Devarakonda, (unknown), Chia‐Chi Lin, Yutaka Fujiwara, Angelika Terbuch, Sophie Postel‐Vinay, Maria-Elisabeth Goebeler, Alfredo Addeo, Hans Prenen, Tobias Arkenau, Adrian G. Sacher, Chunxu Liu, William Kormany, Jordi Rodón	10
6	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis 2022 ·Blood Advances ·Franco Locatelli, Gerhard Zugmaier, Noemi Mergen, Peter Bader, Sima Jeha, Paul‐Gerhardt Schlegel, Jean‐Pierre Bourquin, Rupert Handgretinger, Benoît Brethon, Claudia Rössig, William Kormany, (unknown), Christiane Chen‐Santel	36
7	Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia 2022 ·Pediatric Blood & Cancer ·Michael J. Burke, David S. Ziegler, Francisco Bautista, Andishe Attarbaschi, Lia Gore, Franco Locatelli, Maureen M. O’Brien, Melinda Pauly, William Kormany, (unknown), Christopher Morris, André Baruchel	7
8	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL 2022 ·Leukemia & lymphoma ·Deborah A. Katz, Joan Morris, Michael P. Chu, Kevin A. David, Catherine Thiéblemont, Nicholas Morley, (unknown), Andreas Viardot, Alejandro Martı́n, (unknown), Mariana Bastos‐Oreiro, Seung‐Tae Lee, William Kormany, Yuqi Chen, Hansen Wong, Abraham Anderson, Yuliya V. Katlinskaya, Ariel A. Avilion, Tian Dai, Eva González‐Barca	16
9	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO) 2020 ·Blood ·Franco Locatelli, Gerhard Zugmaier, Noemi Mergen, Peter Bader, Sima Jeha, Paul‐Gerhardt Schlegel, Jean‐Pierre Bourquin, Rupert Handgretinger, Benoît Brethon, Claudia Rössig, William Kormany, (unknown), Christiane Chen‐Santel	1
10	Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse 2020 ·Blood ·Xavier Thomas, Anita W. Rijneveld, Nicola Fracchiolla, Cyril Šálek, Alexandros Spyridonidis, Sabina Chiaretti, (unknown), (unknown), Abeera Mohammad, William Kormany, (unknown), Alessandro Rambaldi	1
11	Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 2018 ·Drug Safety ·Anthony S. Stein, Janet Franklin, Victoria M. Chia, (unknown), William Kormany, (unknown), (unknown), Hamid Amouzadeh, (unknown), (unknown)	37
12	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia 2018 ·Blood Advances ·Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech‐Marańda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp	27
13	Clobazam in the treatment of Lennox‐Gastaut syndrome 2008 ·Epilepsia ·Joan A. Conry, Yu‐Tze Ng, Juliann Paolicchi, (unknown), Wendy G. Mitchell, Frank J. Ritter, Stephen D. Collins, Katherine Tracy, William Kormany, (unknown), (unknown), (unknown)	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact